17Cicada Ltd

17Cicada is a start-up biotechnology company spinning out from the University of Nottingham, pursuing a lean start-up strategy to establish itself as a world leader in the manufacture of commodity and speciality chemicals from waste. 17Cicada is building a biorefinery-based biotechnology platform for the microbial synthesis of zero-carbon or carbon-negati...

Paclitaxel (branded as Taxol) is one of the most important anticancer drugs and has been used for therapy of different types of cancer. It first gained FDA approval in 1992\. The compound, considered a blockbuster anticancer drug, was originally isolated from _Taxus brevifolia_ (Pacific yew), but is now known to be present in the approximately eleven _Tax...

17Cicada anticipates the development of a revolutionary process that will allow individual farms to independently produce their own animal feed in a way that is sustainable, cost effective and with minimal environmental impact. 17Cicada aims to generate a robust and innovative way of utilising wastewater to support the growth of nutritional microalgae tha...

17Cicada anticipates market entry for its bacterial Hyaluronic Acid (HA) by 2025\. Our projected cumulative 5-year profits are of the order of £5.2 million (by 2029), i.e. 1033% return on investment (ROI) on project costs of £506,366 GBP. HA is widely distributed throughout connective, epithelial and neural tissues in human and animal bodies. It plays a s...